



Published in final edited form as:

Int J Oncol. 2008 August ; 33(2): 239–244.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience

Krzysztof Mrózek¹, Andrew J. Carroll², Kati Maharry^{1,3}, Kathleen W. Rao⁴, Shivanand R. Patil⁵, Mark J. Pettenati⁶, Michael S. Watson⁷, Diane C. Arthur⁸, Ramana Tantravahi⁹, Nyla A. Heerema¹⁰, Prasad R. K. Koduru¹¹, AnneMarie W. Block¹², Mazin B. Qumsiyeh¹³, Colin G. Edwards¹, Lisa J. Sterling¹, Kelsi B. Holland^{1,3}, and Clara D. Bloomfield¹

¹Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

²University of Alabama at Birmingham, Birmingham, AL

³The CALGB Statistical Center, Duke University Medical Center, Durham, NC

⁴University of North Carolina at Chapel Hill, Chapel Hill, NC

⁵University of Iowa, Iowa City, IA

⁶Wake Forest University Medical Center, Winston Salem, NC

⁷American College of Medical Genetics, Bethesda, MD

⁸National Cancer Institute, Bethesda, MD

⁹Dana-Farber Cancer Institute, Boston, MA

¹⁰Department of Pathology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

¹¹North Shore University Hospital, Manhasset, NY

¹²Roswell Park Cancer Institute, Buffalo, NY

¹³Duke University Medical Center, Durham, NC

Abstract

The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in maintaining accurate, high quality cytogenetic data for clinical and translational studies using two criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e. adequate) cases, the proportion of karyotypes whose interpretation was changed on central karyotype review. We compared the first four years during which central karyotype review was performed with a recent four-year period and found that the proportion of rejected samples decreased significantly for both AML and ALL. However, during the latter period, central karyotype reviews still found 8% of AML and 16% of ALL karyotypes inadequate. Among adequate cases, the karyotype was revised in 26% of both AML and ALL samples. Some revisions

resulted in changing the patients' assignment to particular World Health Organization diagnostic categories and/or moving patients from one prognostic group to another. Overall, when both data on rejection rates and data on karyotype revisions made in accepted cases were considered together, 32% of AML and 38% of ALL samples submitted were either rejected or revised on central karyotype review during the recent 4-year period. These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies.

Keywords

karyotyping; chromosome aberrations; human; correlative studies; acute leukemia

Introduction

Cytogenetic findings have become an integral part of diagnosis, prognostication and therapeutic stratification of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Such recurrent chromosome abnormalities and their molecular equivalents as $t(8;21)(q22;q22)/RUNX1-RUNX1T1$, $inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11$, $t(15;17)(q22;q12-21)/PML-RARA$, and balanced abnormalities involving band 11q23 and the *MLL* gene are now included in the World Health Organization (WHO) classification of AML, and together with morphology, immunophenotype and clinical features are being used to define distinct disease entities (1). Notably, the role of cytogenetics will be substantially increased in the 2008 revision of the WHO classification (2).

Moreover, pretreatment cytogenetic findings constitute one of the most important prognostic factors in both AML (3–10) and ALL (7,11–13), are used to determine postremission therapy (14–17), and are important for molecular genetic studies investigating mutations (18–29) and changes in expression of specific genes (30–32), as well as gene- (33–37) and microRNA-expression (38,39) profiles in patients with acute leukemias. Importantly, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology specify that cytogenetic analysis is an obligatory part of the diagnostic workup in AML (40). Likewise, cytogenetic analysis is one of the minimum laboratory requirements for the diagnosis of AML according to the “Guidelines on the Management of Acute Myeloid Leukaemia in Adults” issued by the British Committee for Standards in Haematology (41). Consequently, the Cancer and Leukemia Group B (CALGB) now mandates cytogenetic analyses for adult AML and ALL front-line treatment trials and many correlative studies. It is therefore imperative that cytogenetic data are accurate.

Despite continuous improvements in cytogenetic methodology, not all cytogenetic studies of bone marrow (BM) or blood from patients with acute leukemia are successful. In addition to a fraction of cases in which BM or blood cultures yield no mitotic cells, some cytogenetic preparations from leukemic samples are of suboptimal quality. This can make correct interpretation of karyotypes difficult. It has long been recognized that metaphase chromosomes of leukemic cells (especially, but not exclusively, from ALL patients) often have poor morphology with indistinct banding (42). Furthermore, a remarkable heterogeneity of chromosome findings in acute leukemias, with over two hundred recognized recurrent aberrations, many of which are relatively rare having been reported in less than 10 cases worldwide (43–45), underscores the necessity for cytogeneticists analyzing patients with AML and ALL to have vast experience in leukemia cytogenetics.

Therefore, CALGB pioneered the central review of karyotypes, which has been performed biannually since 1986 (46). In the current study, we evaluated the role of central karyotype

review in providing accurate cytogenetic data. Our analysis shows an improvement in the quality of submitted karyotypes over time but also confirms the continued need for performing central karyotype review in the multi-institutional cooperative group setting to obtain the best possible data for clinical and translational studies.

Patients and Methods

Cytogenetic analyses of diagnostic (n=5259) and relapse (n=909) samples from patients with AML and ALL enrolled onto a prospective cytogenetic companion study, CALGB 8461 (5), were performed in multiple, currently 33, CALGB-approved institutional cytogenetic laboratories. Written IRB-approved informed consent was obtained from all patients. For each specimen, two karyotypes and metaphase spreads from each clone were submitted with the data on processing methods to the CALGB Cytogenetic Data Management Center. If applicable, images of interphase and/or metaphase cells subjected to fluorescence *in situ* hybridization (FISH) were also submitted. All cases underwent biannual central karyotype review performed by the CALGB Karyotype Review Committee consisting often expert cancer cytogeneticists. At central karyotype review sessions, every karyotype, metaphase spread, FISH image, and processing and interpretive data were reviewed by two cytogeneticists. In some cases, usually those with more complex chromosome abnormalities and/or with suboptimal banding quality, other reviewers also rendered their opinion. Once consensus was reached, each submission was judged as either acceptable with adequate banding quality, acceptable with borderline banding quality, or inadequate and consequently rejected. Reasons for rejection included poor banding quality that makes unequivocal karyotype interpretation impossible, and, only in cases with a normal karyotype, analysis of <20 metaphase cells from a marrow sample cultured for 24–48 hours or analysis of blood only (5). Since the aim of this study was to assess the role of central karyotype review, our analyses did not include 202 AML and 125 ALL cases for whom cytogenetic analysis yielded no metaphase cells.

In addition to data on rejection rates collected routinely at each central karyotype review, for the purpose of this study, we prospectively collected detailed information on the reasons for revisions made by central karyotype review in the submitted karyotypes that were accepted or borderline accepted during eight recent central karyotype review sessions. The reasons for revision were divided into the following categories: 1) major errors in karyotype interpretation, such as failure of the submitting laboratory to recognize a clonal abnormality, identification of an abnormality found on central karyotype review not to be present, and incorrect interpretation of an abnormality; 2) the need for refinement of breakpoint assignment in structural abnormalities properly recognized by the submitting laboratory, 3) misidentified or upside-down chromosomes, and 4) incorrect use of the ISCN (1995) nomenclature (47). In this study, we excluded samples analyzed cytogenetically during complete remission, because these samples differ from pretreatment and relapse samples in that they rarely contain leukemic cells and are usually karyotypically normal (48). The rejection rates between the first and the recent four-year periods (Table I) have been compared using the Fisher's Exact test. All analyses were performed by the CALGB Statistical Center.

Results and Discussion

Table I shows rejection rates and reasons for rejection for AML and ALL specimens that underwent central karyotype review during the entire period between 1986 and 2006. Overall, 12% of 4991 AML and 23% of 1177 ALL karyotypes submitted were rejected. The most common reason for rejection was inadequate banding quality, which accounted for rejection of 53% (325 of 612) of AML and 46% (123 of 270) of ALL inadequate cases.

When we compared rejection rates between the first four years during which central karyotype review was performed and the recent four-year period, we found a significant improvement in the quality of submitted specimens in both AML ($P < 0.0001$) and ALL ($P < 0.001$). This was mainly due to the significant decrease in the numbers of karyotypes with inadequate banding quality (AML, $P < 0.0001$ and ALL, $P = 0.02$). Nevertheless, the recent central karyotype reviews still found 8% of AML and 16% of ALL samples inadequate.

Another indication of the quality improvement over time was an increase in the proportion of abnormal karyotypes pretreatment, from 52% in the first 4 years to 57% in the recent 4 years ($P = 0.05$) in AML and from 59% to 75% in ALL ($P = 0.007$). These improvements in quality can be attributed to many factors, including progress in cell culturing, harvesting and banding techniques, as well as increase in proficiency in analyzing specimens from patients with acute leukemias. The latter has been achieved in part through feedback provided to cytogeneticists from the submitting laboratories after central karyotype review sessions and through educational workshops organized and conducted by the members of the Karyotype Review Committee during CALGB Group Meetings.

Among karyotypes deemed to have adequate banding at 8 recent Central Karyotype Review sessions, changes in karyotype interpretation were made in 26% of both AML and ALL cases (Table II). The revisions included identification of an unrecognized chromosome abnormality or reinterpretation of an abnormality incorrectly interpreted by the submitting laboratory (44% of all revisions), reassignment of breakpoints in structural aberrations (22%), correction of misidentified or upside-down chromosomes (22%), and correction of errors in the ISCN (1995) nomenclature (12%).

In several instances, major changes in karyotype interpretation made on central karyotype review resulted in moving patients from one diagnostic category in the current WHO classification (1) to another. For example, AML patients whose karyotypes submitted as normal were revised to abnormal ones that harbored $t(9;11)(p22;q23)$, $t(11;19)(q23;p13.1)$ or $inv(16)(p13q22)$, as well as patients whose submitted karyotype was changed from $46,X,-Y,+8$ to $46,X,-Y,+8,t(9;11)(p22;q23)$, from $46,XX,t(10;11)(p14;q13)$ to $46,XX,ins(10;11)(p12;q23q13)$, from $46,XY,del(5)(q13q33),del(11)(q23)$ to $46,XY,del(5)(q13q33),t(6;11)(q27;q23)$, and from $46,XY,del(3)(p13),add(11)(q23),-18,-21,+mar$ to $46,XY,t(3;11)(p13;q23),add(18)(q21),-21$ would be reclassified from having “AML not otherwise categorized” to “AML with recurrent cytogenetic abnormalities”. Conversely, the patient whose submitted complex karyotype included an $inv(16)(p13q22)$ that was revised on central karyotype review to $der(16)add(16)(p13)del(16)(q22)$ would be reclassified from having “AML with recurrent cytogenetic abnormalities” to “AML not otherwise categorized”. There would be multiple additional changes in diagnostic categories once the new 2008 edition of the WHO classification (2) is published, including, for example, a reclassification from “AML with myelodysplasia related changes” to “AML with recurrent genetic abnormalities” for the patient whose karyotype submitted as normal was found on central karyotype review to contain an $inv(3)(q21q26)$.

Many of both the aforementioned and other karyotype revisions made on central karyotype review resulted in changes in prognostic group assignment of the patients. For instance, revisions from a normal karyotype to a karyotype containing $inv(3)(q21q26)$ or $t(11;19)(q23;p13.1)$, or from $del(11)(q23)$ to $t(6;11)(q27;q23)$ meant that these patients were no longer classified as having an intermediate risk but were included in the adverse risk category instead (5). Poor prognosis associated with an isolated trisomy of chromosome 13 (49) was no longer predicted in a patient whose karyotype was revised from $47,XY,+13$ to $47,XY,+15$ when the reviewers discovered that an extra chromosome submitted as

chromosome 13 was in fact an extra chromosome 15 placed upside-down in the karyotype of borderline quality. To date, prognostic significance of isolated trisomy 15 is unclear and it has been suggested to represent a benign, age-related abnormality in older male patients (50,51). Moreover, identification of an initially unrecognized *inv(16)* alters the patient's risk assignment from intermediate to favorable, whereas revision of the submitted *inv(16)* to *der(16)add(16)(p13)del(16)(q22)* as part of a complex karyotype means that the patient's risk-group assignment is no longer favorable but becomes adverse. Importantly, documentation of the presence or absence of *inv(16)* is of major clinical importance (52) because the postremission therapy of AML patients with *inv(16)* on CALGB protocols is administered in a risk-adapted fashion and includes three courses of high-dose cytarabine, whereas patients without *inv(16)* [or *t(8;21)*] receive autologous peripheral stem-cell transplantation (15).

Finally, we evaluated both the data on karyotype revisions made in the accepted cases and data on rejection rates during the recent 4-year period. Overall, 32% of AML and 38% of ALL samples submitted were either rejected or revised on central karyotype review.

While several studies have addressed the issue of proficiency testing and quality control in clinical cytogenetics (53–55), to our knowledge only one other study (from the Children's Oncology Group), published in abstract form, has reported the cooperative group experience concerning central review of karyotypes from acute leukemia patients (Heerema, *et al*, Cytogenet Genome Res 106: 136, 2004). Results of this study are remarkably similar to ours, showing that the karyotype was either changed or rejected in 31% of AML and 49% of ALL pediatric cases submitted. Therefore, we conclude that central karyotype review plays a vital role in ensuring the validity of the clinical trials and correlative studies conducted by both adult and children's cooperative groups.

Acknowledgments

This study was supported in part by National Cancer Institute, Bethesda, MD grants CA77658, CA101140, CA31946, CA16058, CA47545, CA47559, CA47642, CA77440, CA16450, CA32291, CA35279, CA47577 and CA02599, and The Coleman Leukemia Research Foundation.

References

1. Jaffe, ES.; Harris, NL.; Stein, H.; Vardiman, JW., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
2. Swerdlow, S.; Campo, E.; Harris, NL.; Jaffe, ES.; Pileri, S.; Stein, H., editors; Thiele, J.; Vardiman, JW., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; In press
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. *Blood*. 1998; 92:2322–2333. [PubMed: 9746770]
4. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. *Blood*. 2000; 96:4075–4083. [PubMed: 11110676]
5. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*. 2002; 100:4325–4336. [PubMed: 12393746]
6. Haferlach T, Kern W, Schoch C, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. *Haematologica*. 2004; 89:408–418. [PubMed: 15075074]

7. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. *Blood Rev.* 2004; 18:115–136. [PubMed: 15010150]
8. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, Döhner H. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. *Blood.* 2006; 108:3280–3288. [PubMed: 16840728]
9. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *Blood.* 2006; 108:63–73. [PubMed: 16522815]
10. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. *Biol Blood Marrow Transplant.* 2007; 13:655–664. [PubMed: 17531775]
11. Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. *Blood.* 1999; 93:3983–3993. [PubMed: 10339508]
12. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. *Blood.* 2005; 105:3434–3441. [PubMed: 15650057]
13. Moorman AV, Harrison CJ, Buck GAN, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood.* 2007; 109:3189–3197. [PubMed: 17170120]
14. Schlenk RF, Benner A, Hartmann F, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. *Leukemia.* 2003; 17:1521–1528. [PubMed: 12886238]
15. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. *J Clin Oncol.* 2004; 22:4290–4301. [PubMed: 15514371]
16. Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). *Am J Hematol.* 2007; 82:1056–1062. [PubMed: 17696203]
17. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood.* 2005; 106:3760–3767. [PubMed: 16105981]
18. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult *de novo* acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of *FLT3*: a Cancer and Leukemia Group B study. *Cancer Res.* 2001; 61:7233–7239. [PubMed: 11585760]
19. Fröhling S, Schlenk RF, Breitnick J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood.* 2002; 100:4372–4380. [PubMed: 12393388]
20. Fröhling S, Schlenk RF, Stolze I, et al. *CEBPA* mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. *J Clin Oncol.* 2004; 22:624–633. [PubMed: 14726504]
21. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. *Blood.* 2005; 106:3733–3739. [PubMed: 16076867]
22. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (*NPM1*) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. *Blood.* 2005; 106:3740–3746. [PubMed: 16051734]

23. Whitman SP, Ruppert AS, Radmacher MD, et al. *FLT3* D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking *FLT3* internal tandem duplications. *Blood*. 2008; 111:1552–1559. [PubMed: 17940205]
24. Paschka P, Marcucci G, Ruppert AS, et al. Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. In press.
25. Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? *Blood*. 2007; 109:431–448. [PubMed: 16960150]
26. Schnittger S, Kohl TM, Haferlach T, et al. *KIT*-D816 mutations in *AML1-ETO*-positive AML are associated with impaired event-free and overall survival. *Blood*. 2006; 107:1791–1799. [PubMed: 16254134]
27. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of *KIT* mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. *J Clin Oncol*. 2006; 24:3904–3911. [PubMed: 16921041]
28. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with *AML1/RUNX1* mutations and increased *FLT3* expression in acute myeloid leukemia. *Blood*. 2007; 110:1308–1316. [PubMed: 17485549]
29. Mrózek K. Cytogenetic, molecular genetic and clinical characteristics of acute myeloid leukemia with a complex karyotype. *Semin Oncol*. In press.
30. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. *BAALC* expression and *FLT3* internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. *J Clin Oncol*. 2006; 24:790–797. [PubMed: 16418499]
31. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (*MNI*) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. *Blood*. 2006; 108:3898–3905. [PubMed: 16912223]
32. Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the *ETS*-related gene, *ERG*, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. *J Clin Oncol*. 2007; 25:3337–3343. [PubMed: 17577018]
33. Lindvall C, Furge K, Björkholm M, et al. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. *Haematologica*. 2004; 89:1072–1081. [PubMed: 15377468]
34. Schoch C, Kohlmann A, Dugas M, Kern W, Hiddemann W, Schnittger S, Haferlach T. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. *Leukemia*. 2005; 19:1224–1228. [PubMed: 15902281]
35. Lee S, Chen J, Zhou G, et al. Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. *Proc Natl Acad Sci USA*. 2006; 103:1030–1035. [PubMed: 16418266]
36. Radmacher MD, Marcucci G, Ruppert AS, et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. *Blood*. 2006; 108:1677–1683. [PubMed: 16670265]
37. Andersson A, Ritz C, Lindgren D, et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. *Leukemia*. 2007; 21:1198–1203. [PubMed: 17410184]
38. Garzon R, Volinia S, Liu C-G, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. *Blood*. 2008; 111:3183–3189. [PubMed: 18187662]
39. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008; 358:1919–1928. [PubMed: 18450603]
40. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology - v. 1.2008. Acute Myeloid Leukemia. Accessed March 7, 2008 http://www.nccn.org/professionals/physician_gls/PDF/aml.pdf

41. Milligan DW, Grimwade D, Cullis JO, et al. British Committee for Standards in Haematology. Guidelines on the management of acute myeloid leukaemia in adults. *Br J Haematol.* 2006; 135:450–474. [PubMed: 17054678]
42. Sandberg, AA. *The chromosomes in human cancer and leukemia.* 2nd ed. New York: Elsevier; 1990.
43. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. *Best Pract Res Clin Haematol.* 2001; 14:19–47. [PubMed: 11355922]
44. Johansson B, Mertens F, Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. *Ann Med.* 2004; 36:492–503. [PubMed: 15513300]
45. Mitelman, F.; Johansson, B.; Mertens, F., editors. [2/2008 update] Mitelman database of chromosome aberrations in cancer. 2008. <http://cgap.nci.nih.gov/Chromosomes/Mitelman>
46. Bloomfield CD, Mrózek K, Caligiuri MA. Cancer and Leukemia Group B Leukemia Correlative Science Committee: major accomplishments and future directions. *Clin Cancer Res.* 2006; 12:3564s–3571s. [PubMed: 16740786]
47. Mitelman, F., editor. *ISCN (1995): An International System for Human Cytogenetic Nomenclature.* Basel: Karger; 1995.
48. Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. *J Clin Oncol.* 2004; 22:2410–2418. [PubMed: 15197203]
49. Farag SS, Archer KJ, Mrózek K, et al. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *Int J Oncol.* 2002; 21:1041–1051. [PubMed: 12370753]
50. Smith A, Watson N, Sharma P. Frequency of trisomy 15 and loss of the Y chromosome in adult leukemia. *Cancer Genet Cytogenet.* 1999; 114:108–111. [PubMed: 10549265]
51. Hanson CA, Steensma DP, Hodnefield JM, et al. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. *Am J Clin Pathol.* 2008; 129:478–485. [PubMed: 18285273]
52. Mrózek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol.* 2001; 19:2482–2492. [PubMed: 11331327]
53. Hoeltge GA, Dewald G, Miles J, Palmer C. Proficiency testing in clinical cytogenetics. The 1986 experience of the College of American Pathologists. *Arch Pathol Lab Med.* 1988; 112:1085–1090. [PubMed: 3178421]
54. Hoeltge GA, Dewald G, Palmer CG, et al. Proficiency testing in clinical cytogenetics. A 6-year experience with photographs, fixed cells, and fresh blood. *Arch Pathol Lab Med.* 1993; 117:776–779. [PubMed: 8343040]
55. Held K, Eiben B, Miny P. The long-term effect of external quality assessment on performance in service cytogenetics. *Cytogenet Cell Genet.* 2000; 91:124–127. [PubMed: 11173843]

Appendix

The following Cancer and Leukemia Group B institutions, principal investigators, and cytogeneticists participated in this study:

Wake Forest University School of Medicine, Winston-Salem, NC: David D. Hurd, Harold O. Goodman, P. Nagesh Rao, Wendy L. Flejter and Mark J. Pettenati (grant no. CA03927); North Shore University Hospital, Manhasset, NY: Daniel R. Budman, Natalie B. Kardon and Prasad R. K. Koduru (grant no. CA35279); Roswell Park Cancer Institute, Buffalo, NY: Ellis G. Levine, Avery A. Sandberg and AnneMarie W. Block (grant no. CA02599); The Ohio State University Medical Center, Columbus, OH: Clara D. Bloomfield, Karl S. Theil, Diane Minka and Nyla A. Heerema (grant no. CA77658); Dana-Farber Cancer Institute, Boston, MA: Eric P. Winer, Ramana Tantravahi, Cynthia C. Morton, Leonard L. Atkins and

Paola Dal Cin (grant no. CA32291); Duke University Medical Center, Durham, NC: Jeffrey Crawford, Sandra H. Bigner, Mazin B. Qumsiyeh and Barbara K. Goodman (grant no. CA47577); Weill Medical College of Cornell University, New York, NY: John Leonard, Ram S. Verma,* Prasad R. K. Koduru, Andrew J. Carroll and Susan Mathew (grant no. CA07968); University of Maryland Cancer Center, Baltimore, MD: Martin Edelman, Joseph R. Testa, Deana Hallman, Stuart Schwartz, Maimon M. Cohen, Judith Stamberg and Yi Ning (grant no. CA31983); University of Iowa Hospitals, Iowa City, IA: Gerald H. Clamon and Shivanand R. Patil (grant no. CA47642); University of Chicago Medical Center, Chicago, IL: Gini Fleming, Diane Roulston, Katrin M. Carlson, Yanming Zhang and Michelle M. Le Beau (grant no. CA41287); University of North Carolina, Chapel Hill, NC: Thomas Shea and Kathleen W. Rao (grant no. CA47559); Washington University School of Medicine, St. Louis, MO: Nancy L. Bartlett, Christine G. Janney, Eric C. Crawford, Jaime Garcia-Heras and Michael S. Watson (grant no. CA77440); Dartmouth Medical School, Lebanon, NH: Marc S. Ernstoff, Doris H. Wurster-Hill* and Thuluvancheri K. Mohandas (grant no. CA04326); Rhode Island Hospital, Providence, RI: William Sikov, Teresita Padre-Mendoza, Jennifer A. Ahearn, Philip L. Townes, Hon Fong L. Mark, Shelly L. Kerman and Aurelia Meloni-Ehrig (grant no. CA08025); University of Alabama at Birmingham: Robert Diasio and Andrew J. Carroll (grant no. CA47545); SUNY Upstate Medical University, Syracuse, NY: Stephen L. Graziano, Navnit S. Mitter, Edward J. Hallinan, Lawrence P. Gordon and Constance K. Stein (grant no. CA21060); Christiana Care Health Services, Inc., Newark, DE: Stephen S. Grubbs, Digamber S. Borgaonkar, Jeanne M. Meck and Kathleen Richkind (grant no. CA45418); University of Missouri/Ellis Fischel Cancer Center, Columbia, MO: Michael C. Perry, Judith H. Miles, Jeffrey R. Sawyer, Tim H. Huang and Linda M. Pasztor (grant no. CA12046); Long Island Jewish Medical Center CCOP, Lake Success, NY: Kanti R. Rai, Alan L. Shanske and Prasad R. K. Koduru (grant no. CA11028); Minneapolis VA Medical Center, Minneapolis, MN: Vicki A. Morrison and Sugandhi A. Tharapel (grant no. CA47555); University of California, San Diego, CA: Barbara A. Parker, Oliver W. Jones, E. Robert Wassman, Renée Bernstein* and Marie L. Dell'Aquila (grant no. CA11789); Walter Reed Army Medical Center, Washington, DC: Thomas Reid, Rawatmal B. Surana, Syed K. Rafi, Doris H. Wurster-Hill,* Digamber S. Borgaonkar, Karl S. Theil, Diane Minka, Nyla A. Heerema and Kathleen E. Richkind (grant no. CA26806); Parkview Hospital, Ft. Wayne, IN: Sreenivasa Nattam and Patricia I. Bader; University of Minnesota, Minneapolis, MN: Bruce A. Peterson, Betsy A. Hirsch and Diane C. Arthur (grant no. CA16450); Mount Sinai School of Medicine, New York, NY: Lewis R. Silverman and Vesna Najfeld (grant no. CA04457); University of Massachusetts Medical School, Worcester, MA: William W. Walsh, Philip L. Townes, Vikram Jaswaney Kathleen E. Richkind, Michael J. Mitchell and Patricia Miron (grant no. CA37135); Massachusetts General Hospital, Boston, MA: Jeffrey W. Clark, Cynthia C. Morton, Paola Dal Cin and Leonard L. Atkins (grant no. CA12449); Eastern Maine Medical Center, Bangor, ME: Harvey M. Segal and Laurent J. Beauregard (grant no. CA35406); University of Vermont, Burlington, VT: Hyman B. Muss, Elizabeth F. Allen and Mary Tang (grant no. CA77406); Western Pennsylvania Hospital, Pittsburgh, PA: Richard K. Shaddock and Gerard R. Diggans; University of Illinois, Chicago, IL: David J. Peace, Maureen M. McCorquodale, Kathleen E. Richkind and Valerie Lindgren (grant CA74811); Medical College of Virginia/Virginia Commonwealth University, Richmond, VA: John D. Roberts and Colleen Jackson-Cook (grant no. CA52784); Columbia-Presbyterian Medical Center, New York, NY: Rose R. Ellison and Dorothy Warburton (grant no. CA12011); Finsen Institute, Copenhagen, Denmark: Nis I. Nissen and Preben Philip; McGill Department of Oncology, Montreal, Quebec: J. L. Hutchison and Jacqueline Emond (grant no. CA31809); University of Puerto Rico School of Medicine, San Juan, PR: Eileen I. Pacheco, Ramana Tantravahi, Cynthia C. Morton, Paola Dal Cin and Leonard L. Atkins; Georgetown University Medical Center, Washington, DC: Minnetta C. Liu and Jeanne M. Meck (grant no. CA77597); SUNY Maimonides Medical Center, Brooklyn, NY: Sameer Rafla and Ram S. Verma* (grant no.

CA25119); University of Nebraska Medical Center, Omaha, NE: Anne Kessinger and Warren G. Sanger (grant no. CA77298); Medical University of South Carolina, Charleston, SC: Mark R. Green, Eduardo S. Cantu, G. Shashidhar Pai and Dayna J. Wolff (grant no. CA03927); University of California, San Francisco, CA: Charles J. Ryan, Athena M. Cherry and Kathleen E. Richkind (grant no. CA60138); Southern Nevada Cancer Research Foundation CCOP, Las Vegas, NV: John Ellerton, Oliver W. Jones, E. Robert Wassman, Renée Bernstein* and Marie L. Dell'Aquila (grant no. CA35421); University of Cincinnati Medical Center, Cincinnati, OH: Orlando J. Martelo and Ashok K. Srivastava (grant no. CA47515); Kansas City CCOP, Kansas City, MO: Rakesh Gaur and Linda Cooley; South East Cancer Control Consortium, Winston-Salem, NC: James N. Atkins and Mark J. Pettenati (grant no. CA45808).

*Deceased.

Rejection rates and reasons for rejection by central karyotype review among AML and ALL cases enrolled onto CALGB 8461

Table 1

Disease	Reason for rejection	All samples	First 4 years	Recent 4 years	P-value ^d
AML	No. of samples reviewed	4991	934	1126	
	No. (%) of samples rejected	612 (12%) ^b	196 (21%) ^b	90 (8%) ^b	<0.0001
	inadequate banding (%)	325 (53%)	149 (76%)	26 (29%)	<0.0001
	normal BM karyotype and <20 cells (%) ^c	168 (27%)	20 (10%)	40 (44%)	<0.0001
ALL	normal karyotype in blood only (%) ^d	115 (19%)	26 (13%)	23 (26%)	0.02
	No. of samples reviewed	1177	222	128	
	No. (%) of samples rejected	270 (23%)	74 (33%)	20 (16%)	<0.001
	inadequate banding (%)	123 (46%)	49 (66%)	7 (35%)	0.02
	normal BM karyotype and <20 cells (%) ^c	78 (29%)	13 (18%)	9 (45%)	0.02
	normal karyotype in blood only (%) ^d	69 (26%)	12 (16%)	4 (20%)	0.74

^a Comparisons of the rejection rates between the first 4 years and the recent 4 years of central karyotype reviews were calculated using Fisher's exact test.

^b Samples from 4 AML cases, including 1 reviewed during the first 4 year and 1 during the recent 4 year periods, were rejected due to the inability of the submitting laboratory to provide sufficient documentation for suspected abnormalities.

^c BM denotes bone marrow.

^d Cytogenetic analysis of bone marrow was either not performed or was unsuccessful.

Table II

Changes in karyotype interpretation made in accepted AML and ALL cases during 8 recent central karyotype review sessions

Changes in karyotype interpretation made by central karyotype review	Total n=1138	AML n=1031	ALL n=107
No. (%) of samples revised ^a	300 (26%)	272 (26%)	28 (26%)
Total no. of changes made ^a	446	404	42
Type of revision:			
Recognition of a missed abnormality or change in abnormality description (%)	195 (44%)	176 (43%)	19 (45%)
Change in breakpoint(s) assignment (%)	100 (22%)	83 (21%)	17 (40%)
Correction of misidentified or upside-down chromosome(s) (%)	98 (22%)	95 (24%)	3 (7%)
Correction in ISCN (1995) nomenclature (%)	53 (12%)	50 (12%)	3 (7%)

^aSome karyotypes required two or more corrections.